Deadly brain infection in German MS patient prompts Roche investigation

Reuters, 24 May 2017
Authors: John Miller, Bill Berkrot, Greg Mahlich and Lisa Shumaker
“A person in Germany treated with Roche Holding AG’s new multiple sclerosis drug Ocrevus has been diagnosed with an often-deadly brain infection after switching from another medication earlier this year. Roche said it was investigating a case of Progressive Multifocal Leukoencephalopathy (PML) in a patient previously being treated for three years with Biogen Inc’s Tysabri and who had received a single dose of Ocrevus in February. Ocrevus was approved in the United States in March.”
Find article here.